Homo sapiens v-myb myeloblastosis viral oncogene homolog (avian)-like 2 (MYBL2)
Synonyms:
B-MYB; BMYB
Immunogen
A phospho specific peptide corresponding to residues surrounding threonine 487 of human B-Myb was used as an immunogen. This antibody detects B-Myb phosphorlyated on threonine 487.
Buffer
50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
Expression of the B-Myb transcription factor is upregulated during late G1 phase of the cell cycle by an E2F-dependent transcriptional mechanism. B-Myb is specifically phosphorylated during S phase, suggesting that a cyclin-dependent kinase (Cdk) regulates its activity. Consistent with this notion, the S phase-specific cyclin A/Cdk2 was found previously to enhance B-Myb transactivation activity in cotransfected cells. There is evidence that B-Myb is a direct physiological target for cyclin A/Cdk2. Data indicate that phosphorylation by cyclin A/Cdk2 is directly involved in enhancing B-Myb transactivation activity and that levels of endogenous cyclin A/Cdk2 activity may contribute to cell line-specific B-Myb function (1). Nuclear entry of B-Myb is dependent on multiple nuclear localization signals (NLS's). Mutagenesis of the putative NLS's of B-Myb has identified two separate NLS's, NLS1 and NLS2. Each of the two NLS's is essential for efficient nuclear targeting (2).
Related Pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis on Raji cell lysates using anti-Phospho-B-Myb (pT487), 1:1000 dilution. Cells were either (A) untreated (B) treated with TPA + IGF
